Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VLX-1005 and Argatroban Interaction Study
NCT05325346Phase 1Completed
- Sponsor
- Veralox Therapeutics
- Start
- Mar 2022
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of VLX-1005 in heparin-induced thrombocytopenia (HIT) (3 arms), sponsored by Veralox Therapeutics. Primary endpoints: Maximum Observed Plasma Concentration (Cmax) of VLX-1005, Maximum Observed Plasma Concentration (Cmax) of Argatroban and 6 more. Started Mar 2022; status: completed.
02
Drugs
VLX-1005
03
Conditions
heparin-induced thrombocytopenia (HIT)
Beyond the preview
Go deeper on NCT05325346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05325346.